MK 458

Known as: 2H-Naphth(1,2-b)-1,4-oxazin-9-ol, 3,4,4a,5,6,10b-hexahydro-4-propyl-, hydrochloride, (4aR-trans)-, MK-458 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-1992
01219881992

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
 
Is this relevant?
1992
1992
Adjunctive treatment with the very potent and selective dopamine D-2 agonist MK-458 (controlled-release formulation) improved the… (More)
Is this relevant?
1992
1992
To investigate the pharmacokinetic profile, bioavailability, and dose proportionality of the D2-agonist MK-458… (More)
Is this relevant?
1991
1991
The potent and selective dopamine D-2 agonist, MK-458 [PHNO; (+)-4-propyl-9-hydroxynaphthoxazine] was administered as monotherapy… (More)
Is this relevant?
1991
1991
Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458… (More)
Is this relevant?
1990
1990
4-Propyl-9-hydroxynaphthoxazine, or MK-458 (HPMC), a selective, nonergot D2 agonist administered orally twice a day in sustained… (More)
Is this relevant?
1988
1988
MK 458 is a potent and selective D2 receptor agonist. MK 458 consists of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in a… (More)
Is this relevant?